Ingrid Mayer

Ingrid Mayer is a breast oncologist and clinical investigator who has contributed to advancing targeted therapy in triple-negative breast cancer including PI3K pathway inhibitors and PARP inhibitors. She has been involved in clinical trials examining novel therapeutic combinations in TNBC and has contributed to understanding of molecular determinants of response and resistance. She leads clinical research in breast cancer at Vanderbilt-Ingram Cancer Center and is engaged in mentoring the next generation of breast cancer investigators. Her work spans from early phase trials to biomarker-driven treatment development.